Geller Family Office Services LLC Acquires Shares of 100,000 AcelRx Pharmaceuticals, Inc. (ACRX)

Geller Family Office Services LLC acquired a new position in shares of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 100,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $460,000. AcelRx Pharmaceuticals makes up 0.2% of Geller Family Office Services LLC’s holdings, making the stock its 18th biggest holding. Geller Family Office Services LLC owned about 0.20% of AcelRx Pharmaceuticals at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in ACRX. Bank of New York Mellon Corp increased its stake in AcelRx Pharmaceuticals by 6.6% during the first quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock worth $355,000 after acquiring an additional 6,942 shares during the last quarter. WealthTrust Axiom LLC increased its stake in AcelRx Pharmaceuticals by 50.0% during the second quarter. WealthTrust Axiom LLC now owns 210,000 shares of the specialty pharmaceutical company’s stock worth $451,000 after acquiring an additional 70,000 shares during the last quarter. LMR Partners LLP acquired a new stake in AcelRx Pharmaceuticals during the second quarter worth $319,000. Virtu KCG Holdings LLC increased its stake in AcelRx Pharmaceuticals by 600.9% during the second quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock worth $255,000 after acquiring an additional 101,742 shares during the last quarter. Finally, Goldman Sachs Group Inc. acquired a new stake in AcelRx Pharmaceuticals during the second quarter worth $530,000. Hedge funds and other institutional investors own 13.94% of the company’s stock.

In other news, insider Lawrence G. Hamel sold 10,161 shares of AcelRx Pharmaceuticals stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $5.29, for a total value of $53,751.69. Following the completion of the sale, the insider now directly owns 16,379 shares of the company’s stock, valued at $86,644.91. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Mark G. Edwards acquired 30,000 shares of the company’s stock in a transaction dated Tuesday, November 14th. The stock was purchased at an average cost of $1.90 per share, with a total value of $57,000.00. Following the completion of the purchase, the director now directly owns 150,000 shares of the company’s stock, valued at approximately $285,000. The disclosure for this purchase can be found here. Insiders bought 42,000 shares of company stock valued at $89,380 over the last ninety days. Insiders own 28.10% of the company’s stock.

Several equities research analysts have issued reports on the company. HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of AcelRx Pharmaceuticals in a research note on Friday, October 27th. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $2.00 price objective on shares of AcelRx Pharmaceuticals in a research note on Friday, October 13th. Royal Bank Of Canada dropped their price objective on AcelRx Pharmaceuticals from $6.00 to $5.00 and set an “outperform” rating for the company in a research note on Friday, October 13th. Jefferies Group cut AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, October 13th. Finally, ValuEngine cut AcelRx Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, October 12th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $6.83.

Shares of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) opened at $2.25 on Monday. AcelRx Pharmaceuticals, Inc. has a one year low of $1.55 and a one year high of $5.75. The company has a debt-to-equity ratio of -0.43, a quick ratio of 4.71 and a current ratio of 4.78.

TRADEMARK VIOLATION NOTICE: This story was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.com-unik.info/2017/12/04/geller-family-office-services-llc-acquires-shares-of-100000-acelrx-pharmaceuticals-inc-acrx.html.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Want to see what other hedge funds are holding ACRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX).

Institutional Ownership by Quarter for AcelRx Pharmaceuticals (NASDAQ:ACRX)

What are top analysts saying about AcelRx Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AcelRx Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit